Ticker >

Vaishali Pharma share price

Vaishali Pharma Ltd.

NSE: VAISHALI SECTOR: Pharmaceuticals & Drugs  21k   37   1

162.00
+6.20 (3.98%)
NSE: 23 Apr 03:59 PM

Price Summary

Today's High

₹ 164.85

Today's Low

₹ 154.25

52 Week High

₹ 203.6

52 Week Low

₹ 114.85

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

173.65 Cr.

Enterprise Value

186.33 Cr.

No. of Shares

1.07 Cr.

P/E

29.76

P/B

4.51

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  35.96

CASH

0.98 Cr.

DEBT

13.66 Cr.

Promoter Holding

26.32 %

EPS (TTM)

₹  5.44

Sales Growth

-8.12%

ROE

22.26 %

ROCE

21.92%

Profit Growth

64.12 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-8.12%
3 Year5.05%
5 Year0.55%

Profit Growth

1 Year64.12%
3 Year486.19%
5 Year52.62%

ROE%

1 Year22.26%
3 Year14.51%
5 Year9.42%

ROCE %

1 Year21.92%
3 Year17.04%
5 Year13.56%

Debt/Equity

0.4144

Price to Cash Flow

160.85

Interest Cover Ratio

4.92066657802597

CFO/PAT (5 Yr. Avg.)

0.96146382484057

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 26.32 0
Dec 2023 26.62 0
Sep 2023 26.62 0
Jun 2023 26.74 0
Mar 2023 26.74 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 486.186873440287% for the Past 3 years.
  • The company has significantly decreased its debt by 7.0987 Cr.
  • Company’s PEG ratio is 0.464089475740551.
  • Company has a healthy liquidity position with current ratio of 2.26617354480195.

 Limitations

  • The company has shown a poor revenue growth of 5.05331046331683% for the Past 3 years.
  • Company has high debtor days of 293.715996916575.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 20.09 26.24 13.42 12.57 27.9
Total Expenditure 16.53 25.46 11.11 9.91 24.94
Operating Profit 3.56 0.78 2.31 2.66 2.95
Other Income 0.53 0.53 0.36 0.3 0.47
Interest 0.42 0.54 0.43 0.47 0.44
Depreciation 0.12 0.15 0.12 0.12 0.12
Exceptional Items 0 0 0 0 0
Profit Before Tax 3.55 0.62 2.12 2.36 2.86
Tax 0.89 0.19 0.53 0.66 0.75
Profit After Tax 2.66 0.44 1.59 1.7 2.11
Adjusted EPS (Rs) 2.52 0.41 1.5 1.61 1.99

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 75.09 60.09 53.77 75.82 69.66
Total Expenditure 73.01 59.18 51.13 68.94 60.28
Operating Profit 2.08 0.9 2.65 6.89 9.38
Other Income 1.98 2.17 1.81 1.79 2.23
Interest 2.66 2.56 2.63 2.49 2.26
Depreciation 0.27 0.44 0.43 0.46 0.5
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.13 0.08 1.4 5.73 8.85
Tax 0.42 0.05 0.36 1.7 2.24
Net Profit 0.71 0.03 1.05 4.02 6.6
Adjusted EPS (Rs.) 0.68 0.03 0.99 3.82 6.26

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 6.59 10.55 10.55 10.55 10.55
Total Reserves 14.81 10.84 11.87 15.81 29.99
Borrowings 4.78 4.05 4.03 3.11 5.23
Other N/C liabilities -0.02 0.23 0.26 0.07 0.93
Current liabilities 42.48 40.42 59.26 51.94 32.07
Total Liabilities 68.64 66.08 85.98 81.46 78.75
Assets
Net Block 1.34 1.49 1.22 1.18 1.98
Capital WIP 0 0 0 0 0
Intangible WIP 0.04 0.08 0.05 0.49 0.67
Investments 0.43 0.43 0.43 0.43 0.43
Loans & Advances 0.89 0.93 0.96 1.43 1.43
Other N/C Assets 2.98 1.94 2.03 1.5 1.56
Current Assets 62.97 61.21 81.3 76.43 72.67
Total Assets 68.64 66.08 85.98 81.46 78.75
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1.13 0.08 1.4 5.73 8.85
Adjustment 1.66 5.78 3.45 1.62 1.16
Changes in Assets & Liabilities 1.62 -1.91 -2.78 -5.2 -7.36
Tax Paid -0.1 -0.72 -0.06 -0.83 -1.56
Operating Cash Flow 4.31 3.22 2.01 1.32 1.08
Investing Cash Flow -0.28 -0.02 -0.11 -0.85 0.28
Financing Cash Flow -3.99 -3.14 -1.81 0.42 -1.73
Net Cash Flow 0.04 0.06 0.09 0.89 -0.37

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 26.74 26.74 26.62 26.62 26.32
atul arvindbhai vasani 21.45 21.45 21.35 21.35 21.10
bharti kiritkumar tolia 0.67 0.67 0.67 0.67 0.67
jagruti atul vasani 4.55 4.55 4.53 4.53 4.48
punita kaushik gandhi 0.04 0.04 0.04 0.04 0.04
vaishali a vasani 0.03 0.03 0.03 0.03 0.03
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 73.26 73.26 73.38 73.38 73.68
bipinbhai devabhai raval - - 1.17 1.49 2.12
nupur anil shah 5.94 6.22 6.14 6.05 7.71
riddhi sanjay aggarwal - - 1.73 1.51 1.31
sapan anil shah 7.26 8.21 8.57 8.73 9.09
vardhilal shivrambhai tha... - - - - 1.09
margi jigneshbhai shah 2.36 2.35 2.22 2.22 -
jainam broking limited - - 4.82 - -
kamini k vora - 1.02 1.01 - -
l7 hitech private limited... - - 1.28 - -
mayadevi k kabra - - 1.89 - -
amaysha textiles private ... 1.09 1.09 - - -
dishant milanbhai parikh 3.82 3.45 - - -
seema aggarwal . 1.90 1.90 - - -

Annual Reports

No Annual reports exist for this company.Report us

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Vaishali Pharma - Quaterly Results2 Feb 2024, 12:00PM Vaishali Pharma - Quaterly Results2 Feb 2024, 12:00PM Vaishali Pharma - Quaterly Results2 Feb 2024, 12:00PM Vaishali Pharma bags order from African Continent28 Nov 2023, 11:40AM Vaishali Pharma - Quaterly Results7 Aug 2023, 12:00PM Vaishali Pharma - Quaterly Results7 Aug 2023, 12:00PM Vaishali Pharma - Quaterly Results7 Aug 2023, 12:00PM Vaishali Pharma - Quaterly Results22 May 2023, 12:00PM Vaishali Pharma - Quaterly Results22 May 2023, 12:00PM Vaishali Pharma - Quaterly Results22 May 2023, 12:00PM Vaishali Pharma bags order worth $73.85 million28 Feb 2023, 2:50PM Vaishali Pharma - Quaterly Results6 Feb 2023, 12:00PM Vaishali Pharma - Quaterly Results6 Feb 2023, 12:00PM Vaishali Pharma - Quaterly Results6 Feb 2023, 12:00PM Vaishali Pharma, Jark Pharma enter into partnership 21 Dec 2022, 2:25PM Vaishali Pharma - Quaterly Results3 Nov 2022, 12:00PM Vaishali Pharma - Quaterly Results3 Nov 2022, 12:00PM Vaishali Pharma - Quaterly Results3 Nov 2022, 12:00PM Vaishali Pharma - Quaterly Results25 Jul 2022, 12:00PM Vaishali Pharma - Quaterly Results25 Jul 2022, 12:00PM Vaishali Pharma partners with Sankalp LifeCare19 Apr 2022, 3:09PM Vaishali Pharma - Quaterly Results21 Jan 2022, 12:00PM Vaishali Pharma bags orders from Nicaragua, Madagascar28 Jun 2021, 11:09AM Vaishali Pharma receives order in excess of $100,000 from Russia22 Jun 2021, 11:08AM Vaishali Pharma launches series of Immunity booster products 14 Jun 2021, 11:05AM Vaishali Pharma bags order worth $270,000 from Afghanistan22 Apr 2021, 11:17AM Vaishali Pharma initiates registration of 30 products in Central African Countries16 Apr 2021, 10:43AM Vaishali Pharma bags yet another bulk order of Rs 32.00 crore14 Jan 2021, 11:22AM Vaishali Pharma enters into licensing agreement with U.S.A. Healthcare market4 Jan 2021, 11:40AM Vaishali Pharma successfully delivers large bulk order worth Rs 16 crore1 Jan 2021, 5:07PM Vaishali Pharma gets approval, registration for five new products31 Dec 2020, 10:45AM Vaishali Pharma secures first Bulk order worth Rs 16.00 crore 29 Dec 2020, 10:45AM Vaishali Pharma launches personal care, hygiene products29 Apr 2020, 3:06PM

Vaishali Pharma Stock Price Analysis and Quick Research Report. Is Vaishali Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Vaishali Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Vaishali Pharma cash from the operating activity was Rs 1.0796 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Vaishali Pharma has a Debt to Equity ratio of 0.4144 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Vaishali Pharma , the EPS growth was 64.1155348203287 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Vaishali Pharma has OPM of 13.4621347404928 % which is a bad sign for profitability.
     
  • ROE: Vaishali Pharma have a healthy ROE of 22.2618152641852 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Vaishali Pharma is Rs 162. One can use valuation calculators of ticker to know if Vaishali Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Vaishali Pharma
X